FDA Warns Against Long-Term Use Of Osteoporosis Drugs

Law360, New York (May 10, 2012, 1:31 PM EDT) -- Prolonged use of popular osteoporosis drugs such as Merck & Co. Inc.’s Fosamax and Novartis AG’s Reclast might best be limited to the highest-risk patients because of concern over serious side effects and diminishing benefits, the U.S. Food and Drug Administration said Wednesday.

The agency’s findings, published in the New England Journal of Medicine, concern a class of drugs known as bisphosphonates and come on the heels of labeling updates recommended last year.

Extensive litigation has surrounded negative consequences of the pharmaceuticals, which have been linked...
To view the full article, register now.